Stepwise combination of simple noninvasive fibrosis scoring systems increases diagnostic accuracy in nonalcoholic fatty liver disease

Journal of Clinical Gastroenterology

Volumn 47, Issue 8, 2013, Pages 719-726

  Demir, Münevver ^a   Lang, Sonja ^a   Nierhoff, Dirk ^a   Drebber, Uta ^a   Hardt, Aline ^a   Wedemeyer, Inga ^a   Schulte, Sigrid ^a   Quasdorff, Maria ^a   Goeser, Tobias ^a   Töx, Ulrich ^a   Steffen, Hans Michael ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Liver fibrosis; Nonalcoholic fatty liver disease (NAFLD); Noninvasive tests

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; PIOGLITAZONE;

ADULT; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; BARD FIBROSIS SCORE; CALORIC RESTRICTION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EXERCISE; FEMALE; FIB 4 SCORE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NAFLD SCORE; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; UNIVERSITY HOSPITAL;

ADULT; BIOPSY; FATTY LIVER; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84883213493     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182819a89     Document Type: Article

References (35)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346: 1221-1231.
2. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study. Hepatology. 2005;42: 44-52.
3. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37: 1202-1219.
4. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121: 91-100.
5. Adams LA, Harmsen S, Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol. 2010;105: 1567-1573.
6. Gholam PM, Flancbaum L, Machan JT, et al. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102: 399-408.
7. Targher G, Bertolini G, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30: 1212-1218.
8. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44: 865-873.
9. Söderberg C, Stål P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51: 595-602.
10. Ratziu V, Charlotte F, Heurtier A. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128: 1898-1906.
11. Santos VN, Leite-Mór MMB, Kondo M, et al. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in nonalcoholic fatty liver disease. Braz J Med Biol Res. 2005;38: 747-753.
12. Yoneda M, Mawatari H, Fujita K, et al. High-sensitivity Creactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol. 2007;42: 573-582.
13. Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103: 1372-1379.
14. Nazal L, Riquelme A, Solís N, et al. Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients. Obes Surg. 2010;20: 1400-1407.
15. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125: 437-443.
16. Horoz M, Bolukbas C, Bolukbas FF, et al. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterol. 2005;5: 35.
17. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci. 2010;55: 560-578.
18. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127: 1704-1713.
19. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology. 2008;47: 455-460.
20. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45: 846-854.
21. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57: 1441-1447.
22. Sterling RK, Lissen E, Clumeck N, et al. For the APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43: 1317-1325.
23. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7: 1104-1112.
24. Miller MH, Ferguson MA, Dillon JF. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. Liver Int. 2011;31: 461-473.
25. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6: 6.
26. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94: 2467-2474.
27. Kleiner DE, Brunt EM, Van Natta M, et al. For the nonalcoholic steatohepatitis clinical research network. design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41: 1313-1321.
28. Centis E, Marzocchi R, Di Domizio S. The effect of lifestyle changes in non-alcoholic fatty liver disease. Dig Dis. 2010;28: 267-273.
29. Sanyal AJ, Chalasani N, Kowdley KV. Pioglitazone, Vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362: 1675-1685.
30. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134: 1682-1698.
31. Lydatakis H, Hager I-P, Kostadelou E, et al. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int. 2006;26: 864-871.
32. Sebastiani G, Vario A, Guido M, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol. 2006;44: 686-693.
33. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33: 525-540.
34. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5 year prospective study of 13,369 examinations. Hepatology. 2010;51: 828-835.
35. McPherson S, Stewart SF, Henderson E, et al. Simple noninvasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59: 1265-1269.